Mostrar el registro sencillo del ítem
dc.contributor.author
Fraunhoffer Navarro, Nicolas Alejandro
dc.contributor.author
Chanez, Brice
dc.contributor.author
Teyssedou, Carlos
dc.contributor.author
Iovanna, Juan L.
dc.contributor.author
Mitry, Emmanuel
dc.contributor.author
Dusetti, Nelson J.
dc.date.available
2024-12-12T12:41:40Z
dc.date.issued
2023-03
dc.identifier.citation
Fraunhoffer Navarro, Nicolas Alejandro; Chanez, Brice; Teyssedou, Carlos; Iovanna, Juan L.; Mitry, Emmanuel; et al.; A Transcriptomic-Based Tool to Predict Gemcitabine Sensitivity in Advanced Pancreatic Adenocarcinoma; W B Saunders Co-Elsevier Inc; Gastroenterology; 164; 3; 3-2023; 476-480.e4
dc.identifier.issn
0016-5085
dc.identifier.uri
http://hdl.handle.net/11336/250338
dc.description.abstract
Pancreatic ductal adenocarcinoma (PDAC) is most often diagnosed at an advanced stage that is not amenable to surgery. Therefore, systemic therapy is the only treatment able to improve patients’ outcomes. FOLFIRINOX triychemotherapy is the most effective regimen but comes at the expense of high toxicity. Gemcitabine-based regimens are the typical alternative and have varying survival and response rates. Therefore, establishing a potent stratification method to categorise chemotherapeutic efficacy would improve prognosis by allowing treatment to be tailored. All consecutive patients treated for a locally advanced or metastatic PDAC with first-line gemcitabine monotherapy were retrospectively recorded and included after archived FFPE tumour block recovery. RNA-seq data were obtained from 65 primary tumour and 36 metastasis samples. Patients were stratified by gemcitabine response profile using four RNA-based gemcitabine response signatures on the overall survival (OS) and progression-free survival (PFS). The GemCore signature achieved the best performance in discriminating gemcitabine-sensitive patients, defined as GemCore+, in both OS (P<0.0001) and PFS (P<0.0001). GemCore+ patients had a median OS of 13.9 months (95% CI: 9.51–17.18) and a median PFS of 4.85 months (95% CI: 4.29–8.07) versus a GemCore- OS of 3.1 months (95% CI: 2.33–4.79) and PFS of 1.15 months (95% CI: 0.49–1.87). We also explored the ability of GemCore to stratify biopsies from metastasis. Here, GemCore+ patients had an OS of 6.6 months (95% CI: 4.72–16.13) and PFS of 2.95 months (95% CI: 1.38–4.36) versus a GemCore- OS of 2.1 months (95% CI: 1.64–3.48) and PFS of 0.36 months (95% CI: 0.00–1.34). The RNA-based GemCore stratification predicted the benefit of gemcitabine in patients with advanced PDAC in samples obtained from primary tumours and metastatic sites.
dc.format
application/pdf
dc.language.iso
eng
dc.publisher
W B Saunders Co-Elsevier Inc
dc.rights
info:eu-repo/semantics/openAccess
dc.rights.uri
https://creativecommons.org/licenses/by-nc-nd/2.5/ar/
dc.subject
PDAC
dc.subject
Gemcitabine
dc.subject
Metastasis
dc.subject.classification
Patología
dc.subject.classification
Medicina Básica
dc.subject.classification
CIENCIAS MÉDICAS Y DE LA SALUD
dc.title
A Transcriptomic-Based Tool to Predict Gemcitabine Sensitivity in Advanced Pancreatic Adenocarcinoma
dc.type
info:eu-repo/semantics/article
dc.type
info:ar-repo/semantics/artículo
dc.type
info:eu-repo/semantics/publishedVersion
dc.date.updated
2024-11-25T15:21:31Z
dc.journal.volume
164
dc.journal.number
3
dc.journal.pagination
476-480.e4
dc.journal.pais
Estados Unidos
dc.journal.ciudad
Philadelphia
dc.description.fil
Fil: Fraunhoffer Navarro, Nicolas Alejandro. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Centro de Estudios Farmacológicos y Botánicos. Universidad de Buenos Aires. Facultad de Medicina. Centro de Estudios Farmacológicos y Botánicos; Argentina
dc.description.fil
Fil: Chanez, Brice. Inserm; Francia. Centre National de la Recherche Scientifique; Francia
dc.description.fil
Fil: Teyssedou, Carlos. Inserm; Francia. Centre National de la Recherche Scientifique; Francia
dc.description.fil
Fil: Iovanna, Juan L.. No especifíca;
dc.description.fil
Fil: Mitry, Emmanuel. Centre National de la Recherche Scientifique; Francia. Inserm; Francia
dc.description.fil
Fil: Dusetti, Nelson J.. No especifíca;
dc.journal.title
Gastroenterology
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.1053/j.gastro.2022.11.035
Archivos asociados